MIRA Pharmaceuticals, Inc. is a clinical development stage biopharmaceutical company. The Company is focused on the development and commercialization of molecular synthetic cannabinoid analog for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. The Company is developing its product candidate, MIRA1a, for the treatment of neuropsychiatric, inflammatory and neurologic diseases and disorders. MIRA1a is a synthetic cannabinoid analog for treating anxiety and chronic pain by striking a balance between the beneficial effects of tetrahydrocannabinol (THC) and cannabidiol (CBD) by targeting the cannabinoid type 1 and type 2 (CB1 and CB2) receptors.